Effects of perindopril on aldosterone production in the failing human heart

Yuji Mizuno1, Hirofumi Yasue, Michihiro Yoshimura

  • 1Division of Cardiovascular Medicine, Kumamoto Aging Research Institute, Kumamoto, Japan. aldo@poppy.ocn.ne.jp

Insights

Angiotensin-converting enzyme (ACE) inhibition with perindopril suppresses cardiac aldosterone production in heart failure patients. This occurs by reducing ACE activity within the heart, indicating aldosterone is activated in failing ventricles.

Area of Science:

  • Cardiology
  • Pharmacology
  • Endocrinology

Background:

  • Heart failure is associated with activated cardiac aldosterone production.
  • The role of cardiac angiotensin-converting enzyme (ACE) in this process is not fully understood.
  • Understanding the mechanisms of aldosterone regulation in heart failure is crucial for therapeutic development.

Purpose of the Study:

  • To investigate whether ACE inhibition suppresses cardiac aldosterone production in patients with heart failure.
  • To determine the effect of perindopril on cardiac ACE activity and aldosterone levels.
  • To explore the relationship between cardiac ACE activity and aldosterone production in the failing heart.

Main Methods:

  • A randomized controlled trial involving 41 patients with left ventricular systolic dysfunction.
  • Patients were assigned to receive either perindopril (4 mg/day) or a placebo.
  • Plasma levels of aldosterone and ACE activity were measured in the anterior interventricular vein, coronary sinus, and aortic root via cardiac catheterization.

Main Results:

  • In the placebo group, aldosterone and ACE activity were significantly higher in the anterior interventricular vein and coronary sinus compared to the aortic root.
  • Perindopril treatment significantly reduced aldosterone and ACE activity in the anterior interventricular vein and coronary sinus compared to placebo.
  • A significant positive correlation was observed between the difference in aldosterone and ACE activity between the anterior interventricular vein and aortic root.

Conclusions:

  • Perindopril effectively suppresses cardiac aldosterone production in heart failure patients.
  • This suppression is primarily mediated by the reduction of cardiac ACE activity.
  • Aldosterone production is activated in the failing ventricle and can be modulated by ACE inhibition.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...